The Federal Bureau of Prisons may price comprehensive inmate medical care at a Maryland federal prison against a Medicare rate set for rural West Virginia, the Government Accountability Office held in a decision denying a pre-award protest by incumbent contractor American Correctional Healthcare, Inc. GAO decided the case on July 6, 2026, and the decision appears on GAO's recent bid protest listing under July 14. The protest, docketed as B-424391, challenged the terms of the solicitation rather than an award, and it spotlights a question every offeror on a health services contract eventually confronts: how much does the government's pricing yardstick have to resemble the market where the work gets performed?
Background
American Correctional Healthcare, a small business of Fort Worth, Texas, holds the current contract for comprehensive medical services at the Federal Correctional Institution in Cumberland, Maryland. On March 9, 2026, the Bureau of Prisons issued Request for Proposals No. 15BFA025R00000055, seeking to award a single contract for comprehensive medical services at the facility — work that, in the decision's words, "principally includes specialized medical services that cannot be provided on site."
The solicitation's pricing architecture drew the challenge. Rather than asking offerors for flat rates or a fee schedule of their own construction, the Bureau required each to express its pricing as a discount from, or a premium to, Medicare rates for Core-Based Statistical Area 51, rural West Virginia. Every offeror would quote against the same index, and the agency would compare the resulting percentages.
The incumbent found that arrangement indefensible on its face. Roughly 90 percent of the services provided under the current contract, ACH told GAO, run through Maryland hospitals. Pegging the pricing benchmark to rural West Virginia was arbitrary, the company argued: the rural West Virginia Medicare rate was, in its words, "no more relevant to this procurement than the Fairbanks, Alaska Medicare rate." If the benchmark bore no relationship to where the care is actually purchased, the argument ran, the resulting price evaluation could not be rational. ACH also argued that pricing off Medicare at all departed from customary commercial practice.
The protest landed while the Bureau's institutional health is itself under scrutiny. On July 2, 2026, the agency announced it would close six institutions, a decision Federal News Network reported the Bureau attributed to "extreme staffing challenges." Director William K. Marshall III said the closures were "necessary to address longstanding infrastructure and staffing challenges." The Bureau carries a backlog of more than $4 billion in deferred maintenance, and the American Federation of Government Employees says the agency lost more than 1,400 employees last year, many to Immigration and Customs Enforcement. FCI Cumberland is not on the closure list, and its medical services requirement is moving forward.
Key Details
The Bureau's defense inverted the protester's logic. Yes, the agency conceded, much of the care flows to Maryland facilities, and that is precisely why it declined to use Maryland's Medicare rate. Maryland, the agency told GAO, uses an idiosyncratic Medicare reimbursement formula different from every other state. Choosing a CBSA that relied on a conventional Medicare reimbursement formula, the agency explained, would facilitate its ability to analyze the pricing it received.
The Bureau added a geographic point, and the record supports it. Cumberland sits in Maryland's western panhandle, and the incumbent contract itself relied on hospitals located in Maryland, Pennsylvania, and West Virginia. No single state's rate captures that catchment. A common benchmark, any defensible one, at least ensures competing proposals can be laid side by side and read against each other.
GAO agreed, and the reasoning is narrower than the outcome might suggest. The benchmark, GAO held, was a comparative tool and nothing more. The solicitation permitted offerors to propose pricing reflecting "the desired level of payment for the category of services rendered," which made the choice of CBSA an "administrative convenience" rather than a constraining factor. It did not cap what offerors could charge or dictate what they would pay providers, and the solicitation stated explicitly that it did not restrict pricing flexibility. A yardstick that merely normalizes proposals for comparison need only be reasonably related to the services being procured, not serve as a precise proxy for the local market.
GAO then closed the door a second time, on prejudice. Every offeror faced the identical benchmark, and GAO found all offerors possessed equal information about service locations and provider options. ACH could not articulate a reasonable possibility that the CBSA 51 index disadvantaged it relative to competitors, and without that showing the challenge fails regardless of the benchmark's merits. The published digest states the holding compactly: "Protest challenging solicitation pricing benchmark is denied where the benchmark is reasonably related to the services to be procured, and the protester cannot articulate a reasonable possibility of competitive prejudice."
The decision does not state the contract's value.
What It Means for Contractors
The practical lesson concerns the shape of a winning solicitation challenge, not Medicare geography. Attacking an evaluation benchmark as unrepresentative is a hard road when the benchmark applies equally to everyone. GAO did not weigh whether CBSA 51 is the best available index, or even a good one. It asked whether the index bears a reasonable relationship to the procurement and whether the protester could show harm — two questions answerable without ever reaching the merits of the agency's economic judgment.
Incumbents should read the prejudice holding closely. An incumbent's knowledge of where the work actually goes is real information, and ACH's 90 percent figure is exactly the kind of operational fact competitors lack. But that asymmetry cuts against the protest posture. If the benchmark is uniform, an incumbent's superior grasp of the local market becomes an advantage in pricing against it, not an injury. The company that knows the Maryland cost base best is the company best positioned to convert a West Virginia index into an accurate bid.
There is also a message about agency discretion in pricing methodology. The Bureau's rationale sounds counterintuitive on first hearing: it avoided the local rate because the local rate is unusual. GAO accepted it because the agency tied that choice to the mechanics of Medicare reimbursement and to the multi-state reality of Cumberland's referral pattern. Agencies that can articulate a coherent, documented rationale for a comparison tool will generally survive a terms challenge to it.
Finally, offerors on this kind of work should treat the pricing index as a modeling input, not a constraint. GAO's holding rests on the premise that offerors keep full pricing flexibility, which makes the discount-or-premium figure an output of the bidder's own cost model. The bidder that maps its real provider costs onto the index most accurately, rather than arguing about which index the agency should have picked, is the one that competes.
